Last updated on March 2018

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

Brief description of study

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.

Clinical Study Identifier: NCT02595060

Contact Investigators or Research Sites near you

Start Over

Susanne Herold, MD, PhD

Universities of Marburg and Giessen Lung Center
Giessen, Germany
  Connect »

Kai Zacharowski, Prof. Dr. Dr., ...

Universit tsklinikum Frankfurt, Klinik f r An sthesiologie, Intensivmedizin und Schmerztherapie
Frankfurt, Germany
  Connect »

Tobias Welte, Prof. Dr., MD

Medizinische Hochschule Hannover, Klinik f r Pneumologie
Hannover, Germany
  Connect »

Michael Bauer, MD, Prof. Dr

Universit tsklinikum Jena, Klinik f r An sthesiologie und Intensivmedizin
Jena, Germany
  Connect »

Hinnerk Wulf, MD, Prof. Dr

University Hospital Marburg, Department of Anaesthesiology and Intensive Care Medicine
Marburg, Germany
  Connect »

Stefan Kluge, MD, Prof. Dr.

Universit tsklinikum Hamburg-Eppendorf, Klinik f r Intensivmedizin
Hamburg, Germany
  Connect »